# EDGAR Filing Document

**Accession Number:** 0002012593
**File Stem:** 0001193125-25-156162
**Filing Date:** 2025-7
**Character Count:** 2480
**Document Hash:** 281c65d489271b7efe03ae341caec793
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-156162.hdr.sgml**: 20250806

**ACCESSION NUMBER**: 0001193125-25-156162

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250707

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Rapport Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002012593
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 880724208
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 99 HIGH STREET
- **STREET 2:** SUITE 2100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 857-321-8020

**MAIL ADDRESS:**
- **STREET 1:** 99 HIGH STREET
- **STREET 2:** SUITE 2100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

**VIA EDGAR** 

July 7, 2025

United States Securities and Exchange Commission

Office of Life Sciences

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Rapport Therapeutics, Inc.**  |

---

**Acceleration Request for Registration Statement on Form S-3** 

**Filed July 1, 2025** 

**File No. 333-288444** 

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), Rapport Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the above-referenced registration statement (the "**Registration Statement**") be accelerated to July 9, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Stephanie A. Richards at (617) 570-1927. If you have any questions regarding this request, please contact Stephanie A. Richards of Goodwin Procter LLP at (617) 570-1927.

---

| |
|:---|
| Sincerely, |
| RAPPORT THERAPEUTICS, INC. |
| /s/ Abraham N. Ceesay |
| Abraham N. Ceesay |
| Chief Executive Officer |

---

cc: Troy Ignelzi, *Rapport Therapeutics, Inc.* 

Kingsley L. Taft, *Goodwin Procter LLP*

Stephanie A. Richards, *Goodwin Procter LLP*